– Interview de Martin Peitz, par Aleksandra Boutin : Accessible pour tous (voir ci-dessus)
– Vidéo : Accessible aux abonnés Concurrences+ (voir ci-dessous)
– Audio : Accessible aux abonnés Concurrences+ (voir ci-dessus)
– Synthèse : Accessible aux abonnés Concurrences+ (voir ci-dessus)
– Retranscription : Accessible aux abonnés Concurrences+ (voir ci-dessus)
– Articles Concurrences (Cliquez sur Voir plus ci-dessous) Consultez la section "Prochaines Conferences" pour vous inscrire aux futurs webinaires.
Deni Mantzari introduced the panel mentioning that perhaps no issue had received more attention in antitrust circles in recent years than killer acquisitions. First arising in the context of pharmaceutical transactions, scrutiny has now extended to other industries, with a particular focus on acquisitions in the technology sector. There have been calls for changes in the evidentiary standard for assessing so-called killer acquisitions, from the adoption of a balance-of-powers approach to the reversal of the burden of proof in such cases, motivated by the concern that the potential harm from killer acquisitions in the technology sector might be so important that it warrants an adjustment of the standards that are usually employed in competition cases.